A well-designed secondary analysis of an RCT showing that centralized troponin review identifies clinically meaningful recurrent MI with prognostic significance, but limited by single-trial population and surrogate endpoint focus.
Post hoc exploratory subanalysis of a parent RCT using a calculated variable (estimated total blood volume) to interrogate heterogeneity in a biomarker endpoint; the authors explicitly state findings are hypothesis-generating and require external validation.
This is a vanguard phase report describing trial design, recruitment experiences, and baseline characteristics of 200 randomized participants in an ongoing RCT; no efficacy or safety outcomes are reported.